Shock in the cardiac intensive care unit: Changes in epidemiology and prognosis over time - 23/01/21
, Abdelrahman M. Ahmed, MBBS b, 1 , Saraschandra Vallabhajosyula, MD MS a, b , Barry Burstein, MD b , Meir Tabi, MD a , Gregory W. Barsness, MD a , Joseph G. Murphy, MD a , Patricia J. Best, MD a , Malcolm R. Bell, MD a Background |
There are few studies documenting the changing epidemiology and outcomes of shock in cardiac intensive care unit (CICU) patients. We sought to describe the changes in shock epidemiology and outcomes over time in a CICU population.
Methods |
We included 1859 unique patients admitted to the Mayo Clinic Rochester CICU from 2007 through 2018 with an admission diagnosis of shock. Temporal trends, including mortality, were assessed across 3-year periods.
Results |
Shock comprised 15.1% of CICU admissions during the study period, increasing from 8.8% of CICU admissions in 2007 to 21.6% in 2018 (P < .01 for trend). Mean age was 68 ± 14 years (38% females). Shock was cardiogenic in 65%, septic in 10% and mixed cardiogenic-septic in 15%. Concomitant diagnoses in patients with cardiogenic shock (CS) included acute coronary syndrome (ACS) in 17%, heart failure (HF) in 35% and both in 40%. There was no significant change in the prevalence of individual shock subtypes over time (P > .1). Among patients with CS, the prevalence of ACS decreased and the prevalence of HF increased over time (P < .01). Hospital mortality was highest among patients with mixed shock (39%; P = .05). Among patients with CS, hospital mortality was lower among those with HF compared to those without HF (31% vs. 40%, P < .01). Hospital mortality decreased over time among patients with shock (P < .01) and CS (P = .02).
Conclusions |
The prevalence of shock in the CICU has increased over time, with a substantial prevalence of mixed CS. The etiology of CS has changed over the last decade with HF overtaking ACS as the most common cause of CS in the CICU.
Le texte complet de cet article est disponible en PDF.Abbreviations : ACS, AKI, AMI, AMICS, APACHE, CA, CCCTN, CCI, CICU, CS, ECMO, HF, IABP, ICD, LVAD, MCS, METRIC, PAC, PCI, SD, SIRS, SOFA, STEMI, VF, U.S.
Plan
| No extramural funding was involved in the conduct of this research. The authors have no relevant financial disclosures or conflicts of interest related to this work. |
Vol 232
P. 94-104 - février 2021 Retour au numéro
Article précédent
- Atrial fibrillation is a marker of increased mortality risk in nonischemic heart failure—Results from the DANISH trial
- Rune Boas, Jens Jakob Thune, Steen Pehrson, Lars Køber, Jens C. Nielsen, Lars Videbæk, Jens Haarbo, Eva Korup, Niels Eske Bruun, Axel Brandes, Hans Eiskjær, Anna M. Thøgersen, Berit T. Philbert, Jesper Hastrup Svendsen, Ulrik Dixen
- Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis
- Anubodh S. Varshney, David E. Wang, Ankeet S. Bhatt, Alexander Blood, Musa A. Sharkawi, Hasan K. Siddiqi, Muthiah Vaduganathan, Peter P. Monteleone, Manesh R. Patel, W. Schuyler Jones, Renato D. Lopes, Mandeep R. Mehra, Deepak L. Bhatt, Ajar Kochar
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?